1675PDEURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma

ConclusionsMultiagent chemotherapy was feasible in this patient population. Outcome seems comparable to high-grade osteosarcoma with a non-significant trend for UPS over leiomyosarcoma. Favorable outcome was associated with extremity site, secondary surgery after neoadjuvant chemotherapy, and good response to primary chemotherapy.Legal entity responsible for the studyThe authors.FundingCOSS, SSG, ISG.DisclosureP. Reichardt: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: PharmaMar; Honoraria (institution), Advisory / Consultancy: Lilly; Advisory / Consultancy: Clinigen; Advisory / Consultancy: Deciphera; Advisory / Consultancy: Roche; Honoraria (institution): Amgen. R. Bertulli: Honoraria (self), Speaker Bureau / Expert testimony: Lilly; Honoraria (self), Speaker Bureau / Expert testimony: Italfarmaco; Honoraria (self), Speaker Bureau / Expert testimony: PharmaMar. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research